Archive for the 'Pemetrexed (Alimta)' Category
October 3rd, 2007. Malignant mediastinal tumor with bone formation–mesothelioma or sarcoma?
However, the tumor grew rapidly and spread to the pleura, involved the heart, and the patient succumbed. This is to our knowledge the first report of a sarcomatous mesothelioma with bone formation from environmental exposure to mineral fibers.
Posted in Carboplatin, Case Study, Chemotherapy, Diagnosis & Differentiation, Full Archive, Pemetrexed (Alimta), Pericardial, Pleural, Sarcomatoid, Surgery, Treatment, Tumor Debulking, Type of Assessment:, Type of Mesothelioma: | No Comments »
September 13th, 2007. Pemetrexed: from preclinic to clinic
The wide spectre of activity of pemetrexed confers it a therapeutic advantage with regard to the other antifolates specific of one or other one enzymes. The clinical results show an anti-tumoral activity against non-small lung cancer and in mesothelioma and recently towards other solid tumours, in particular in head an neck, colon and mammary cancers.
September 13th, 2007. Update of pemetrexed in thoracic oncology
7%). The place of pemetrexed in elderly patients is under evaluation.
September 13th, 2007. Pemetrexed development in oncology
Others axes of development remain possible, but the results are stanby or to confirm as in squamous-cell cancer in the head and neck and breast, digestive or urinary tracts cancer. In all the cases, the optimization of the pemetrexed in terms of amount/methods of administration and associations possible because of its profile of tolerance makes of it a molecule of chemotherapy with a future.
September 1st, 2007. Report of a Case of Pericardial Mesothelioma with Liver Metastases Responding Well to Pemetrexed and Platinum-Based Chemotherapy
com Abstract Pericardial mesothelioma remains a disease with a bleak prognosis. We report the case of a patient with metastases to liver and good response to pemetrexed and carboplatin-based combination chemotherapy and consequent prolonged progression-free survival.
Posted in Carboplatin, Case Study, Chemotherapy, Determining Efficacy, Full Archive, Pemetrexed (Alimta), Pericardial, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
August 4th, 2007. Commentary: A Case for Minimizing Folate Supplementation in Clinical Regimens with Pemetrexed Based on the Marked Sensitivity of the Drug to Folate Availability
S. , the addition of folic acid to regimens with pemetrexed should be limited to the lowest recommended level that provides optimal protection from pemetrexed toxicity.
August 4th, 2007. Multidisciplinary Treatment of Malignant Pleural Mesothelioma
However, currently available treatments still appear to have modest results. Further studies are needed to provide evidence-based recommendations for the treatment of early and advanced stages of this disease.
Posted in Chemotherapy, Determining Efficacy, Extrapleural Pneumonectomy (EPP), Full Archive, New & Novel, Pemetrexed (Alimta), Pleural, Radiation, Raltitrexed (Tomudex), Surgery, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
June 28th, 2007. Caffeine markedly sensitizes human mesothelioma cell lines to pemetrexed
Pemetrexed sensitization by caffeine was associated with an increase in pemetrexed-induced phosphorylation of ataxia-telangiectasia-mutated (ATM) and Chk1. These data indicate that caffeine and its analog, theobromine, may be a useful approach to enhance pemetrexed-based chemotherapy.
June 26th, 2007. Peritoneal mesothelioma: an inusual clinical presentation in a patient without exposure to asbestos
The patient received treatment with systemic palliative chemotherapy, cisplatin-pemetrexed. After three cycles, partial response was observed, but the evolution was fatal due to secondary toxicity of chemotherapy.
Posted in Case Study, Causation, Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Full Archive, Pemetrexed (Alimta), PET Scan, Survival, Treatment, Type of Assessment: | No Comments »
June 23rd, 2007. Management of malignant pleural effusion
PET imaging could be of major interest in the diagnosis of mesothelioma and prognosis evaluation. Mesothelioma prognosis has recently been modified by the association of cisplatin with pemetrexed, a new antimetabolite agent, but mesothelioma remains seldom curable.
Posted in Chemotherapy, Cisplatin (Platinol ®), Diagnosis & Differentiation, Full Archive, Immunohistochemistry or IHC, Pemetrexed (Alimta), PET Scan, Pleural, Pleural Effusion, Symptoms & Symptom Management, thoracoscopy, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 25th, 2007. Management options for malignant pleural mesothelioma: clinical and cost considerations
Ongoing clinical trials are comparing chemotherapy and surgery with supportive care in an effort to define the role of different therapies in MPM. MPM treatment is a costly public health issue; after efficacy is proven, additional studies are needed to measure the cost effectiveness of MPM treatment regimens.
Posted in Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, New & Novel, Pemetrexed (Alimta), Pleural, Survival, Treatment, Type of Assessment:, Type of Mesothelioma: | No Comments »
May 25th, 2007. Preclinical studies of the proteasome inhibitor bortezomib in malignant pleural mesothelioma
Bortezomib may improve outcome in MPM patients alone or in combination with standard chemotherapy but the order of administration is likely to be important. This study justifies further evaluation of bortezomib in MPM.
May 24th, 2007. Severe cutaneous toxicity after Pemetrexed as second line treatment for a refractory non small cell lung cancer
Conclusion: Cutaneous toxicity from pemetrexed should be recognised on account of its potential severity. The appearance of skin lesions is an indication for careful follow-up for evidence of Lyell's syndrome for which intensive management is needed.
May 18th, 2007. Pemetrexed in small-cell lung cancer: background and review of the ongoing GALES pivotal trial
An interim analysis will be conducted after 700 patients have been enrolled. The study will also use pharmacogenomic analysis to evaluate biological predictors of response, in particular to pemetrexed.
May 1st, 2007. Sequence-dependent administration of raloxifene and 5-fluorouracil/pemetrexed protects against pemetrexed cytotoxicity in human bone marrow
Conclusion: This study suggests that sequence-dependent administration of RAL (5FU/MTA/RAL), in combination with 5-FU/MTA, protects against MTA toxicity in human bone marrow while maintaining the maximum inhibitory effect of pemetrexed in breast cancer.
April 14th, 2007. Treatment of malignant pleural mesothelioma
As other treatment methods, chemohyperthermia, treatments using various kinds of cytokines and angiogenesis inhibitors, genetic treatment and photodynamic therapy have been attempted. The current treatment results for this disease are very poor, and there has been a strong demand for establishing an effective treatment method.
Posted in Angiogenesis, Chemotherapy, Cisplatin (Platinol ®), Determining Efficacy, Full Archive, Gene Therapy, New & Novel, Pemetrexed (Alimta), Photodynamic Therapy (PDT), Pleural, Treatment, Trimodality Therapy, Type of Assessment:, Type of Mesothelioma: | No Comments »
April 6th, 2007. Pemetrexed Alone or in Combination with Cisplatin in Previously Treated Malignant Pleural Mesothelioma: Outcomes from a Phase IIIB Expanded Access Program.
Conclusions: The data from this EAP study suggest that patients with previously treated MPM can benefit from treatment with pemetrexed alone or in combination with cisplatin. The treatment is associated with acceptable toxicity.
April 6th, 2007. The use of chemotherapy in patients with advanced malignant pleural mesothelioma: a systematic review and practice guideline
Conclusions: There is good evidence to recommend chemotherapy with pemetrexed and cisplatin for adult patients with symptomatic advanced malignant pleural mesothelioma. Such treatment should be administered with supplementation of vitamin B12 and folic acid. If pemetrexed is not available, cisplatin plus raltitrexed is a reasonable alternative.
April 6th, 2007. Pemetrexed as second-line treatment in malignant pleural mesothelioma after platinum-based first-line treatment
Conclusions: Pemetrexed was generally well tolerated with noteworthy activity in malignant pleural mesothelioma after previous platinum-based treatment and may be considered for second-line treatment.
|
|  |
